title: [Efficacy and safety of hormone replacement therapy with levothyroxine in patients with subclinical hypothyroidism and heart failure].
authors.forename: F T
authors.initials: FT
authors.lastname: Ageev
authors.forename: Z N
authors.initials: ZN
authors.lastname: Blankova
authors.forename: E M
authors.initials: EM
authors.lastname: Seredenina
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Riabtseva
authors.forename: A G
authors.initials: AG
authors.lastname: Ovchinnikov
authors.forename: O N
authors.initials: ON
authors.lastname: Svirida
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015415:Biomarkers; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D011788:Quality of Life; D013974:Thyroxine / Q000008:administration & dosage* / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D013974:Thyroxine